Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M

Kiniksa Pharmaceuticals International, plc

ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.
2026 ARCALYST revenue guidance $900-920M; gross-to-net improved to 8.4% from 9.8%.
Cash and short-term investments $414.1M, no debt; increased $170.4M in 2025.
KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 by year-end 2026.
~18% of 14,000 multiple-recurrence patients on ARCALYST; >4,150 prescribers since launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.